|
Report Date : |
29.01.2013 |
IDENTIFICATION DETAILS
|
Name : |
F. HOFFMANN-LA ROCHE AG |
|
|
|
|
Registered Office : |
Grenzacherstrasse 124 4070 Basel/BS |
|
|
|
|
Country : |
Switzerland |
|
|
|
|
Financials (as on) : |
31.12.2011 |
|
|
|
|
Date of Incorporation : |
01.06.1989 |
|
|
|
|
Com. Reg. No.: |
270.3.000.406-0 / 81803 |
|
|
|
|
Legal Form : |
Company limited by shares |
|
|
|
|
Line of Business : |
Manufacture of basic pharmaceutical products |
|
|
|
|
No. of Employees : |
8'000 |
RATING & COMMENTS
|
MIRA’s Rating : |
A |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
Status : |
Good |
|
Payment Behaviour : |
Regular |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 30th, 2012
|
Country Name |
Previous Rating (31.03.2011) |
Current Rating (30.06.2012) |
|
Switzerland |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SWITZERLAND - ECONOMIC OVERVIEW
Switzerland is a peaceful, prosperous, and modern market economy with low unemployment, a highly skilled labor force, and a per capita GDP among the highest in the world. Switzerland's economy benefits from a highly developed service sector, led by financial services, and a manufacturing industry that specializes in high-technology, knowledge-based production. Its economic and political stability, transparent legal system, exceptional infrastructure, efficient capital markets, and low corporate tax rates also make Switzerland one of the world's most competitive economies. The Swiss have brought their economic practices largely into conformity with the EU's, to enhance their international competitiveness, but some trade protectionism remains, particularly for its small agricultural sector. The fate of the Swiss economy is tightly linked to that of its neighbors in the euro zone, which purchases half of all Swiss exports. The global financial crisis of 2008 and resulting economic downturn in 2009 stalled export demand and put Switzerland in a recession. The Swiss National Bank (SNB) during this period effectively implemented a zero-interest rate policy to boost the economy as well as prevent appreciation of the franc, and Switzerland's economy recovered in 2010 with 2.7% growth. The sovereign debt crises currently unfolding in neighboring euro-zone countries pose a significant risk to Switzerland's financial stability and are driving up demand for the Swiss franc by investors seeking a safehaven currency. The independent SNB has upheld its zero-interest rate policy and conducted major market interventions to prevent further appreciation of the Swiss franc, but parliamentarians have urged it to do more to weaken the currency. The franc's strength has made Swiss exports less competitive and weakened the country's growth outlook; GDP growth fell to 2.1% in 2011. Switzerland has also come under increasing pressure from individual neighboring countries, the EU, the US, and international institutions to reform its banking secrecy laws. Consequently, the government agreed to conform to OECD regulations on administrative assistance in tax matters, including tax evasion. The government has renegotiated its double taxation agreements with numerous countries, including the US, to incorporate the OECD standard, and in 2011 it reached deals with Germany and the UK to resolve outstanding issues, particularly the possibility of imposing taxes on bank deposits held by foreigners. These steps will have a lasting impact on Switzerland's long history of bank secrecy.
Source
: CIA
F. Hoffmann-La
Roche AG
Operating
address:
Grenzacherstrasse
124
4070 Basel/BS
Switzerland/CH
Telephone: 061
6881111
Fax: 061
6919391
Web
site: http://www.roche.ch
E-mail: basel.webmaster@roche.com
VAT-No.: CHE105815381
Established: 1896
History: 1896: Established from Fritz Hoffmann-La Roche
Line
of Business: Pharmaceutics
Industry
Division: Manufacturing
Industry-code (NACE): 2110 Manufacture of basic pharmaceutical
products
Import/Export: Export
Quality
certification: ISO 9001
ISO 14001
Banks: UBS Ltd
CS Credit
Suisse
Coverage: Company
Figures: estimated
Employees: 8'000
The company comprises the manufacture and
sales of pharmaceutical and chemical products, vitamins and Diagnostika.
Information on property ownership was not
available.
Company
No: 270.3.000.406-0 / 81803
Legal
form: Company limited by
shares
Registration: 01.06.1989
Legal
status: active
Responsible
Register: Handelsregister des Kantons
Basel-Stadt
History: Date of Incorporation
Statutes: 31.05.1989
Date of
Statutes: 19.06.1997
Entry Deleted Name
active F.
Hoffmann-La Roche AG
active F.
Hoffmann-La Roche Ltd (Name translated)
active F.
Hoffmann-La Roche SA (Name translated)
Entry Deleted Legal domicile
active Basel,
Switzerland
Entry Deleted Address
active Grenzacherstrasse
124, 4058 Basel/BS, Switzerland/CH
Entry Deleted Capital
active Share
Capital CHF 150'000'000, paidup CHF 150'000'000
Entry Deleted Capital Structure
active 150'000
Registered shares of CHF 1'000.--
Entry Deleted Activity (original Language)
24.07.1997 Fabrikation
und Vertrieb pharmazeutischer und chemischer Produkte aller Art. Die
Gesellschaft kann Grundstücke und Immaterialgüterrechte erwerben und veräussern
sowie sich an anderen Unternehmen beteiligen.
Entry Deleted Remarks (original Language)
active Publishing
authority: SHAB.
active Merger:
Aktiven und Passiven der "Priorin AG", in Münchenstein, nach Massgabe
von Art. 748 OR. Da die übernehmende Gesellschaft Eigentümerin sämtlicher
Aktien der übernommenen Gesellschaft ist, findet keine Kapitalerhöhung statt.
active Contribution
in kind/Asset takeover: Betriebliche Aktiven und Passiven der "Roche
Holding AG", in Basel, umfassend Aktiven von CHF 1'766'305'376.22 und
Passiven von CHF 1'277'348'454.09, gemäss Bilanz per 01.01.1989 zum Preis von
CHF 488'956'922.13, wovon CHF 149'998'000.- an das Aktienkapital angerechnet
werden.
15.02.2012 Merger:
Übernahme der Aktiven und Passiven der IMIB Institut für Medizininformatik und
Biostatistik AG, in Basel (CH-270.3.003.052-2), gemäss Fusionsvertrag vom
01.02.2012 und Bilanz per 31.12.2011. Aktiven von CHF 478'775.00 und Passiven
(Fremdkapital) von CHF 25'978.00 gehen auf die übernehmende Gesellschaft über.
Da die übernehmende Gesellschaft sämtliche Aktien der übertragenden
Gesellschaft hält, findet weder eine Kapitalerhöhung noch eine Aktienzuteilung
statt.
24.06.2008 Merger:
Übernahme der Aktiven und Passiven der Barimec Investment AG, in Basel
(CH-270.3.012.671-0), gemäss Fusionsvertrag vom 05.05.2008 und Bilanz per
31.12.2007. Aktiven von CHF 74'902'500.-- und Passiven (Fremdkapital) von CHF
25'109'556.-- gehen auf die übernehmende Gesellschaft über. Da die übernehmende
Gesellschaft sämtliche Aktien der übertragenden Gesellschaft hält, findet weder
eine Kapitalerhöhung noch eine Aktienzuteilung statt.
22.02.2007 Merger:
Übernahme der Aktiven und Passiven der "RoNexus Services AG", in
Basel (CH-270.3.012.997-3) gemäss Fusionsvertrag vom 12.02.2007 und Bilanz per
31.12.2006. Aktiven von CHF 8'648'840.02 und Passiven (Fremdkapital) von CHF
10'256'683.19, d.h. ein Passivenüberschuss von CHF 1'607843.17, gehen auf die
übernehmende Gesellschaft über. Die übernehmende Gesellschaft weist gemäss
Bestätigung des besonders befähigten Revisors frei verwendbares Eigenkapital im
Umfang des Kapitalverlustes und der Überschuldung auf. Da die übernehmende
Gesellschaft sämtliche Aktien der übertragenden Gesellschaft hält, findet weder
eine Kapitalerhöhung noch eine Aktienzuteilung statt.
04.11.2005 Merger:
Übernahme der Aktiven und Passiven der 'Pharmexbio AG', in Zug
(CH-170.3.007.638-5), gemäss Fusionsvertrag vom 20.10.2005 und Bilanz per
31.08.2005. Aktiven von CHF 1'500'000.-- und Passiven (Fremdkapital) von CHF
115'336'000.--, d.h. ein Passivenüberschuss von CHF 113'836'000.--, gehen auf
die übernehmende Gesellschaft über. Gemäss Bestätigung des besonders befähigten
Revisors liegt ein Rangrücktritt im Umfang des Kapitalverlustes und der
Überschuldung vor. Da dieselbe Aktionärin sämtliche Aktien der an der Fusion
beteiligten Gesellschaften hält, findet weder eine Kapitalerhöhung noch eine
Aktienzuteilung statt.
06.12.2004 Merger:
Übernahme der Aktiven und Passiven der "Valorfides AG", in Chur
(CH-350.3.004.123-9), gemäss Fusionsvertrag vom 29.11.2004 und Bilanz per
30.06.2004. Aktiven von CHF 540'786'072.56 und Passiven (Fremdkapital) von CHF
349'172'234.61 gehen auf die übernehmende Gesellschaft über. Da dieselbe
Aktionärin sämtliche Aktien der an der Fusion beteiligten Gesellschaften hält,
findet weder eine Kapitalerhöhung noch eine Aktienzuteilung statt.
06.12.2004 Merger:
Übernahme der Aktiven und Passiven der "Roche Consumer Health Trading
AG", in Basel (CH-160.3.000.337-5), gemäss Fusionsvertrag vom 29.11.2004
und Bilanz per 30.06.2004. Aktiven von CHF 2'155.770.01 und Passiven
(Fremdkapital) von CHF 49'022.80 gehen auf die übernehmende Gesellschaft über.
Da dieselbe Aktionärin sämtliche Aktien der an der Fusion beteiligten
Gesellschaften hält, findet weder eine Kapitalerhöhung noch eine
Aktienzuteilung statt.
06.12.2004 Merger:
Übernahme der Aktiven und Passiven der "Roche Consumer Health Holding
AG", in Basel (CH-270.3.003.183-2), gemäss Fusionsvertrag vom 29.11.2004
und Bilanz per 30.06.2004. Aktiven von CHF 1'527'395.08 und Passiven
(Fremdkapital) von CHF 15'000.-- gehen auf die übernehmende Gesellschaft über.
Da dieselbe Aktionärin sämtliche Aktien der an der Fusion beteiligten
Gesellschaften hält, findet weder eine Kapitalerhöhung noch eine
Aktienzuteilung statt.
06.12.2004 Merger:
Übernahme der Aktiven und Passiven der "NP Investments AG", in Glarus
(CH-160.3.001.126-7), gemäss Fusionsvertrag vom 29.11.2004 und Bilanz per
30.06.2004. Aktiven von CHF 3'022'859.22 und Passiven (Fremdkapital) von CHF
8'004'000.--, d.h. ein Passivenüberschuss von CHF 4'981'140.78, gehen auf die
übernehmende Gesellschaft über. Gemäss Bestätigung des besonders befähigten
Revisors liegen teils Rangrücktritte im Umfang des Kapitalverlustes und der
Überschuldung vor und teils verfügt die übernehmende Gesellschaft über frei
verwendbare Eigenmittel im erforderlichen Umfang. Da dieselbe Aktionärin sämtliche
Aktien der an der Fusion beteiligten Gesellschaften hält, findet weder eine
Kapitalerhöhung noch eine Aktienzuteilung statt.
12.05.2003 Merger:
Die Gesellschaft übernimmt Aktiven von CHF 116'070.-- und Passiven von CHF
3'300.-- der "Roche Center for Medical Genomics, Ltd", in Basel, nach
Massgabe von Art. 748 OR. Da die übernehmende Gesellschaft Eigentümerin
sämtlicher Aktien der zu übernehmenden Gesellschaft ist, findet keine
Kapitalerhöhung statt.
24.07.1997 Reports:
Mitteilungen an die Aktionäre: Briefe.
Title Name
President Dr. Franz B.
Humer, Origin: Küssnacht SZ, Switzerland, Residential address: 8703
Erlenbach/ZH, Switzerland, joint signature of two, Registered since: 06.11.1995
Chief
Executive Dr. Severin
Schwan, Origin: Austria, Residential address: 4125 Riehen/BS, Switzerland,
joint signature of two, Registered since: 22.01.2001
Director Dr. Alan
Hippe, Origin: Germany, Residential address: Riehen, Switzerland, joint signature
of two, Registered since: 14.04.2011
Director Dr.
Gottlieb Keller, Origin: Dörflingen, Switzerland, Residential address: 8001
Zürich/ZH, Switzerland, joint signature of two, Registered since: 20.06.2000
Director Urs
Lauffer, Origin: Uster, Switzerland, Residential address: 8001 Zürich/ZH,
Switzerland, without signature, Registered since: 20.06.2000
Title Name
Director Dr. Thomas
Singer, Origin: Germany, Residential address: Lörrach, Germany, joint signature
of two, Registered since: 31.07.2003
Director Natacha
Theytaz, Origin: Ayer, Switzerland, Residential address: Therwil, Switzerland,
joint signature of two, Registered since: 12.12.2008
Deputy
Director Dr.
Michael Ausborn, Origin: Germany, Residential address: Lörrach, Germany, joint
signature of two, Registered since: 30.01.2006
Deputy
Director Dr.
Wolfgang Göttert, Origin: Germany, Residential address: Lörrach, Germany, joint
signature of two, Registered since: 23.08.2002
Deputy
Director Horst
Hohler, Origin: Germany, Residential address: Rheinfelden, Germany, joint
signature of two, Registered since: 06.11.1995
Deputy
Director Dr.
Jürgen Knöbel, Origin: Germany, Residential address: Binzen, Germany, joint
signature of two, Registered since: 06.04.1999
Deputy
Director Dr.
Hanno Langen, Origin: Germany, Residential address: Steinen Kr. Lörrach,
Germany, joint signature of two, Registered since: 23.08.2002
Deputy
Director Dr.
Klaus Richter, Origin: Germany, Residential address: Lörrach, Germany, joint
signature of two, Registered since: 06.11.1995
Deputy
Director Boris
Zaïtra, Origin: France, Residential address: Basel, Switzerland, joint
signature of two, Registered since: 10.08.2012
Vice-Director Dr. Ralf
Altenburger, Origin: Germany, Residential address: Eimeldingen, Germany, joint signature
of two, Registered since: 15.12.2009
Vice-Director Dr. Michael
Baltes, Origin: Germany, Residential address: Müllheim, Germany, joint
signature of two, Registered since: 23.08.2002
Vice-Director Dr. Alexander
Bausch, Origin: Germany, Residential address: Lörrach, Germany, joint signature
of two, Registered since: 31.10.2001
Vice-Director Dr. Karl Heinz
Bender, Origin: Germany, Residential address: Neuenburg, Germany, joint
signature of two, Registered since: 20.06.2000
Vice-Director Dr. Robert Bloch,
Origin: Endingen, Switzerland, Residential address: Adliswil, Switzerland,
joint signature of two, Registered since: 08.08.2012
Vice-Director Dr. Hans-Joachim
Boehm, Origin: Germany, Residential address: Lörrach, Germany, joint signature
of two, Registered since: 20.06.2000
Vice-Director Dr. Brigitte
Borho, Origin: Germany, Residential address: Rheinau, Germany, joint signature
of two, Registered since: 08.08.2012
Vice-Director Stefan
Brombacher, Origin: Germany, Residential address: Efringen-Kirchen, Germany,
joint signature of two, Registered since: 01.07.2004
Vice-Director Dr. Thomas
Büchele, Origin: Germany, Residential address: Lörrach, Germany, joint
signature of two, Registered since: 20.07.2007
Vice-Director Dr. Christian
Czech, Origin: Germany, Residential address: Grenzach-Wyhlen, Germany, joint
signature of two, Registered since: 08.08.2012
Vice-Director David Drain,
Origin: United Kingdom, Residential address: Hausen im Wiesental, Germany,
joint signature of two, Registered since: 23.08.2002
Vice-Director Dr. Niklas
Engler, Origin: Germany, Residential address: Lörrach, Germany, joint signature
of two, Registered since: 08.08.2012
Vice-Director Dr. Stefan
Frings, Origin: Germany, Residential address: Grenzach-Wyhlen, Germany, joint
signature of two, Registered since: 26.09.2005
Vice-Director Dr. Sabine
Fürst-Recktenwald, Origin: Germany, Residential address: Freiburg im Breisgau,
Germany, joint signature of two, Registered since: 08.08.2012
Vice-Director Dr. Frank
Güthlein, Origin: Germany, Residential address: Freiburg im Breisgau, Germany,
joint signature of two, Registered since: 08.08.2012
Vice-Director Dr. Thorsten
Gutjahr, Origin: Germany, Residential address: Binzen, Germany, joint signature
of two, Registered since: 20.07.2007
Vice-Director Dr. Dirk Halbig,
Origin: Germany, Residential address: Efringen-Kirchen, Germany, joint
signature of two, Registered since: 03.09.2008
Vice-Director Marcel Hammler,
Origin: Germany, Residential address: Lörrach, Germany, joint signature of two,
Registered since: 23.08.2002
Vice-Director Dr. Sven
Hauptmann, Origin: Germany, Residential address: Lörrach, Germany, joint
signature of two, Registered since: 26.09.2005
Vice-Director André-Michael
Hold, Origin: Binningen, Switzerland, Residential address: Binningen,
Switzerland, joint signature of two, Registered since: 19.08.2009
Vice-Director Dr. Angela
Ianni-Hinz, Origin: Germany, Residential address: Well am Rhein, Germany, joint
signature of two, Registered since: 08.08.2012
Vice-Director Dr. Michael Indlekofer,
Origin: Germany, Residential address: Kandern, Germany, joint signature of two,
Registered since: 31.07.2003
Vice-Director Dr. Axel Tobias
Jung, Origin: Germany, Residential address: Efringen-Kirchen, Germany, joint
signature of two, Registered since: 08.08.2012
Vice-Director Dr. Jürgen Koch,
Origin: Germany, Residential address: Horgenzell, Germany, joint signature of
two, Registered since: 31.10.2011
Vice-Director Dr. Siegfried
Krimmer, Origin: Germany, Residential address: Steinen Kr. Lörrach, Germany,
joint signature of two, Registered since: 08.08.2012
Vice-Director Dr. Harald
Kropshofer, Origin: Germany, Residential address: Lörrach, Germany, joint
signature of two, Registered since: 10.08.2012
Vice-Director Dr. Jasper Kunow,
Origin: Germany, Residential address: Lörrach, Germany, joint signature of two,
Registered since: 20.07.2007
Vice-Director Dr. Hermann Lehn,
Origin: Germany, Residential address: Weil am Rhein, Germany, joint signature
of two, Registered since: 26.09.2005
Vice-Director Dr. Andreas
Leiminer, Origin: Germany, Residential address: Grenzach-Wyhlen, Germany, joint
signature of two, Registered since: 10.08.2012
Vice-Director Dr. Thorsten
Lobert, Origin: Germany, Residential address: Lörrach, Germany, joint signature
of two, Registered since: 10.08.2012
Vice-Director Dr. Peer Hendrik
Lorenz, Origin: Germany, Residential address: Freiburg im Breisgau, Germany,
joint signature of two, Registered since: 10.08.2012
Vice-Director Dr. Joachim Lutz,
Origin: Germany, Residential address: Wehr, Germany, joint signature of two,
Registered since: 10.08.2012
Vice-Director Dr. Matthias
Meier, Origin: Germany, Residential address: Grenzach-Wyhlen, Germany, joint
signature of two, Registered since: 10.08.2012
Vice-Director Dr. Myriam
Mendila, Origin: Germany, Residential address: Steinen Kr. Lörrach, Germany,
joint signature of two, Registered since: 31.10.2011
Vice-Director Dr. Wenger
Michael, Origin: Germany, Residential address: Freiburg im Breisgau, Germany,
joint signature of two, Registered since: 26.09.2005
Vice-Director Barbara
Moll-Stützle, Origin: Germany, Residential address: Rheinfelden, Germany, joint
signature of two, Registered since: 18.06.2010
Vice-Director Dr. Lutz Müller,
Origin: Germany, Residential address: Binzen, Germany, joint signature of two,
Registered since: 26.09.2005
Vice-Director Regina Poppe,
Origin: Germany, Residential address: Wittlingen, Germany, joint signature of
two, Registered since: 17.05.1999
Vice-Director Peter Schiessl, Origin:
Germany, Residential address: Palo Alto, United States of America, joint
signature of two, Registered since: 31.10.2011
Vice-Director Dr. Johannes
Schmidt, Origin: Germany, Residential address: Steinen Kr. Lörrach, Germany,
joint signature of two, Registered since: 31.10.2001
Vice-Director Dr. Wolfgang
Schmidt, Origin: Germany, Residential address: Schopfheim-Langenaue, Germany,
joint signature of two
Vice-Director Dr. Wolfram
Schmidt, Origin: Germany, Residential address: Helsinki, Finland, joint signature
of two, Registered since: 11.04.2012
Vice-Director Norbert
Schreiner, Origin: Germany, Residential address: Liebenswiller, France, joint
signature of two, Registered since: 15.12.2009
Vice-Director Sandra Schröder,
Origin: Germany, Residential address: Lörrach, Germany, joint signature of two,
Registered since: 03.09.2008
Vice-Director Dr. Siegfried
Schützinger, Origin: Austria, Residential address: Weil am Rhein, Germany,
joint signature of two, Registered since: 31.10.2001
Vice-Director Dr. Jörg H.
Sitzmann, Origin: Germany, Residential address: Lörrach, Germany, joint
signature of two, Registered since: 01.07.2004
Vice-Director Ralf Smit,
Origin: Germany, Residential address: Well am Rhein, Germany, joint signature
of two, Registered since: 06.09.1999
Vice-Director Dr. Olivia
Spleiss, Origin: Germany, Residential address: Freiburg im Breisgau, Germany,
joint signature of two, Registered since: 10.08.2012
Vice-Director Dr. Ralf Thoma,
Origin: Germany, Residential address: Grenzach-Wyhlen, Germany, joint signature
of two, Registered since: 10.08.2012
Vice-Director Oste Tim, Origin:
Germany, Residential address: Kandern, Germany, joint signature of two,
Registered since: 27.07.2012
Vice-Director Yvonne Ulrich,
Origin: Germany, Residential address: Fischingen, Germany, joint signature of
two, Registered since: 10.08.2012
Vice-Director Robert Vogel,
Origin: Germany, Residential address: Grenzach-Wyhlen, Germany, joint signature
of two
Vice-Director Sven-Olaf Vogt,
Origin: Germany, Residential address: Grenzach-Wyhlen, Germany, joint signature
of two, Registered since: 20.06.2000
Vice-Director Dr. Cornelia
Weber, Origin: Germany, Residential address: Fischingen, Germany, joint
signature of two, Registered since: 23.08.2002
Vice-Director Dr. Peter Wenner,
Origin: Germany, Residential address: Fischingen, Germany, joint signature of
two, Registered since: 31.07.2003
Vice-Director Sebastian Werner,
Origin: Germany, Residential address: Lörrach, Germany, joint signature of two,
Registered since: 31.10.2001
Vice-Director Dr. Iris Wiesel,
Origin: Germany, Residential address: Efringen-Kirchen, Germany, joint
signature of two, Registered since: 31.07.2003
Vice-Director Dr. Joachim Wolf,
Origin: Germany, Residential address: Lörrach, Germany, joint signature of two,
Registered since: 06.09.1999
Vice-Director Florian Zabel,
Origin: Germany, Residential address: Rheinfelden, Germany, joint signature of
two, Registered since: 24.05.2011
Vice-Director Dr. Friederike
Zahm, Origin: Germany, Residential address: Freiburg im Breisgau, Germany,
joint signature of two, Registered since: 24.05.2011
Title Name
Auditor KPMG AG,
Residential address: Basel, Switzerland, Registered since: 20.07.2009
Title Name
Chief
Executive Officer Dr. Severin
Schwan
Consolidation: consolidated
Industry: Trade/Industry
Fiscal year end: 31.12.2011 31.12.2010 31.12.2009 31.12.2008 31.12.2007
Number of months: 12 12 12 12 12
Currency: mil.
CHF mil. CHF mil. CHF mil. CHF mil.
CHF
Statement norm: IAS IAS IAS IAS IAS
Balance Sheet
Intangible fixed
assets 12'969.0 12'855.0 14'266.0 15'474.0 13'181.0
Land and buildings 8'333.0 10'051.0 8'564.0 9'010.0 8'127.0
Other tangible
fixed assets 7'868.0 6'678.0 9'133.0 9'180.0 9'705.0
Tangible fixed
assets 16'201.0 16'729.0 17'697.0 18'190.0 17'832.0
Financial fixed
assets 384.0 428.0 481.0 940.0 1'333.0
other fixed assets 3'790.0 3'396.0 3'642.0 2'881.0 3'185.0
Fixed assets 33'344.0 33'408.0 36'086.0 37'485.0 35'531.0
Stocks 5'060.0 4'972.0 5'648.0 5'830.0 6'113.0
Trade accounts
receivable 9'799.0 9'403.0 10'461.0 9'755.0 9'804.0
Liquid assets 3'854.0 1'841.0 2'442.0 4'915.0 3'755.0
Securities 7'433.0 9'060.0 16'107.0 15'856.0 20'447.0
other trade
accounts 2'066.0 1'821.0 3'318.0 2'248.0 2'715.0
Accruals 20.0 515.0 503.0
Other current
assets 13'373.0 13'237.0 22'370.0 23'019.0 26'917.0
Current assets 28'232.0 27'612.0 38'479.0 38'604.0 42'834.0
Total assets 61'576.0 61'020.0 74'565.0 76'089.0 78'365.0
Capital 160.0 160.0 160.0 160.0 160.0
Other shareholders
funds 11'935.0 9'309.0 7'206.0 44'319.0 45'323.0
Total shareholders
equity 12'095.0 9'469.0 7'366.0 44'479.0 45'483.0
Minority interests 2'387.0 2'193.0 2'048.0 9'343.0 7'960.0
long term debt
(financial debts) 23'459.0 27'857.0 36'143.0 2'972.0 3'834.0
Provisions 991.0 934.0 700.0 654.0 688.0
Other non current
liabilities 6'434.0 5'589.0 6'241.0 6'537.0 5'946.0
Non current
liabilities 30'884.0 34'380.0 43'084.0 10'163.0 10'468.0
short term debt
(financial debts) 3'394.0 2'201.0 6'273.0 1'117.0 3'032.0
Trade accounts
payable 2'053.0 2'068.0 1'299.0 1'053.0 1'188.0
Provisions 1'742.0 2'146.0 1'618.0 804.0 1'517.0
Accruals 5'451.0 4'938.0 7'917.0 5'684.0 5'645.0
other accounts
payable 3'570.0 3'625.0 4'960.0 3'446.0 3'072.0
other current liabilities 10'763.0 10'709.0 14'495.0 9'934.0 10'234.0
Current
liabilities 16'210.0 14'978.0 22'067.0 12'104.0 14'454.0
Shareh. equity,
min. interests + liabilities 61'576.0 61'020.0 74'565.0 76'089.0 78'365.0
Profit and loss
account
Net sales 42'531.0 47'473.0 49'051.0 45'617.0 46'113.0
Other operating
revenue 1'582.0 1'694.0 2'100.0 2'287.0 0.0
Operating revenue 44'113.0 49'167.0 51'151.0 47'904.0 46'113.0
Cost of goods sold 11'942.0 13'293.0 14'615.0 13'661.0 13'743.0
Gross profit 32'171.0 35'874.0 36'536.0 34'243.0 32'370.0
Other operating
expenses 18'717.0 22'388.0 24'259.0 20'319.0 17'902.0
Operating result 13'454.0 13'486.0 12'277.0 13'924.0 14'468.0
Interest revenues 73.0 64.0 179.0 698.0 1'072.0
other financial
revenues 586.0 656.0 613.0 426.0 733.0
Financial income 659.0 720.0 792.0 1'124.0 1'805.0
Interest expenses 2'006.0 2'506.0 1'733.0 214.0 281.0
other financial
expenses 222.0 489.0 1'104.0 673.0 690.0
Financial expenses 2'228.0 2'995.0 2'837.0 887.0 971.0
Financial result -1'569.0 -2'275.0 -2'045.0 237.0 834.0
Result before
extraordinary items 11'885.0 11'211.0 10'232.0 14'161.0 15'302.0
Extraordinary
income 2.0
Extraordinary
Result 0.0 0.0 0.0 0.0 2.0
Result before
taxes 11'885.0 11'211.0 10'232.0 14'161.0 15'304.0
Taxes 2'341.0 2'320.0 1'722.0 3'317.0 3'867.0
Result before
minority interests 9'544.0 8'891.0 8'510.0 10'844.0 11'437.0
minority interests 201.0 225.0 726.0 1'875.0 1'676.0
Result for the
financial year 9'343.0 8'666.0 7'784.0 8'969.0 9'761.0
Cash flow
Depreciation 1'848.0 1'933.0 1'981.0 2'645.0 2'536.0
Cash flow 11'392.0 10'824.0 10'491.0 13'489.0 13'973.0
Cash flow from
operating activities 12'954.0 14'342.0 16'877.0 12'177.0 11'728.0
Investments in
tangible fixed assets 1'959.0 2'671.0 2'984.0 3'139.0 3'519.0
Cash flow from
investing activities -353.0 3'534.0 -2'909.0 -1'722.0 -5'788.0
Cash flow from
financing activities -10'724.0 -18'434.0 -14'768.0 -9'442.0 -5'270.0
Others 136.0 -43.0 -1'673.0 147.0 -125.0
Change in
liquidity 2'013.0 -601.0 -2'473.0 1'160.0 545.0
Liquidity at
beginning of the year 1'841.0 2'442.0 4'915.0 3'755.0 3'210.0
Liquidity at end
ot the year 3'854.0 1'841.0 2'442.0 4'915.0 3'755.0
Notes
Cost of employees 10'300.0 11'934.0 12'080.0 11'129.0 10'767.0
Research and
Development 8'326.0 9'050.0 9'874.0 8'845.0 8'385.0
Added value 26'039.0 27'584.0 26'026.0 28'149.0 28'888.0
Working Capital 12'806.0 12'307.0 14'810.0 14'532.0 14'729.0
Sales per Employee 0.5 0.6 0.6 0.6 0.6
Market
capitalisation 136'102.0 117'563.0 151'296.0 140'678.0 171'060.0
Gross cost land
and buildings 13'087.0 14'731.0 13'076.0 12'483.0 11'299.0
Gross cost other
tangible fixed assets 17'975.0 16'257.0 18'844.0 17'656.0 18'105.0
Gross cost total 31'062.0 30'988.0 31'920.0 30'139.0 29'404.0
Full time units at
year end 80'129 80'653 81'507 80'080 78'604
Employees inland 7'700 7'650 7'500
Employees abroad 73'807 72'430 71'104
Name: Roche Holding AG
City/Country: Basel/BS, Switzerland/CH
No.
of Owner/-s: 1
Owner: The company is domestic
owned.
Class: 100%
Name: Roche Holding AG
City/Country: Basel/BS, Switzerland/CH
Interest: 100.00% voting right,
100.00% capital interest
Class: 100%
Name: Piramed Limited
City/Country: Welwyn Garden
City/Hertfordshire, United Kingdom/GB
Interest: 100.00% voting right,
100.00% capital interest (since 23.05.2008)
Class: 0-9%
Name: bci Betriebs-AG
City/Country: Basel/BS, Switzerland/CH
Interest: 0.00% capital interest
(since 03.07.2002)
Class: 0-9%
Name: BEC AG
City/Country: Gipf-Oberfrick/AG, Switzerland/CH
Interest: 5.00% voting right,
5.00% capital interest
Control date Year No. Amount CHF Status
02.12.2009 2009 0
02.12.2009 2008 1 9'945.-- Legal actions
02.12.2009 2008 1 8'216.-- Opposition filed
02.12.2009 2007 1 2'500'000.-- Opposition filed
02.12.2009 2006 1 2'500'000.-- Opposition filed
An updated legal action check is only
available against proof of interest. e.g. a copy of an enquiry letter, and
order or invoice relating to the subject company.
Debt collection case:
MAY 2011: CHF 134.00, paid.
SEP 2010: CHF 1'121.00, paid.
Financial
Statements: The company does not
disclose any financial statements. Third parties are not permitted any insight
into the financial affairs. It is therefore difficult to make a proper
assessment of the actual situation.
Financial
Situation: The financial situation
is considered to be very good.
Payment
experiences: Payment habits are
considered good.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.53.89 |
|
|
1 |
Rs.84.92 |
|
Euro |
1 |
Rs.72.51 |
INFORMATION DETAILS
|
Report
Prepared by : |
PRL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.